1-8 of 8
Lacey M. Litchfield
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Matthew P. Goetz, Erika P. Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortes, Stephen Johnston, Antonio Llombart-Cussac, Peter A. Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M. Jansen, Lacey M. Litchfield, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2233–2244.
https://doi.org/10.1158/1078-0432.CCR-22-3573
Published: 15 May 2024
View articletitled, Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Open the PDF for Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Sara M. Tolaney, Shom Goel, Jorge Nadal, Hannelore Denys, Manuel R. Borrego, Lacey M. Litchfield, Jiangang Liu, Adams K. Appiah, Yanyun Chen, Fabrice André
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 39–49.
https://doi.org/10.1158/1078-0432.CCR-23-1209
Published: 05 January 2024
View articletitled, Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Open the PDF for Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors

Xi Rao, Yongmei Chen, Julie Beyrer, Emily Nash Smyth, Claudia Morato Guimaraes, Lacey M. Litchfield, Lee Bowman, Garreth W. Lawrence, Amit Aggarwal, Fabrice Andre
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3372–3383.
https://doi.org/10.1158/1078-0432.CCR-22-3843
Published: 01 September 2023
View articletitled, Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors
Open the PDF for Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4587.
https://doi.org/10.1158/1078-0432.CCR-22-2874
Published: 14 October 2022
View articletitled, Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Journal Articles

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1500–1506.
https://doi.org/10.1158/1078-0432.CCR-21-3276
Published: 14 April 2022
View articletitled, Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Includes: Supplementary data
Journal Articles

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4870–4882.
https://doi.org/10.1158/1078-0432.CCR-19-4191
Published: 01 September 2021
View articletitled, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4939.
https://doi.org/10.1158/1078-0432.CCR-21-2431
Published: 01 September 2021
View articletitled, Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Journal Articles

Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment

Iris L. Romero, Abir Mukherjee, Hilary A. Kenny, Lacey M. Litchfield, Ernst Lengyel
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 680–686.
https://doi.org/10.1158/1078-0432.CCR-14-2198
Published: 16 February 2015
View articletitled, Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment
Open the PDF for Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment in another window